Evaxion Extends Phase II Trial with Personalized Cancer Vaccine EVX-01 to Further Enhance Clinical Data Package

Evaxion Biotech A/S will further enhance the data package from its ongoing phase II trial with the company’s lead asset EVX-01 by extending the trial from two to three years. EVX-01 is a personalized cancer vaccine being developed as a treatment for advanced melanoma.